CLOs on the Move

La Jolla Bioengineering Institute

www.ljbi.org

 
La Jolla Bioengineering Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 50K-100K
  • Annual Revenue: $1-10 Million
  • www.ljbi.org
  • 3535 General Atomics Ct Ste 210
    San Diego, CA USA 92121
  • Phone: 858.456.7500

Executives

Name Title Contact Details

Similar Companies

VEXIOM HOLDINGS CORPORATION

VEXIOM HOLDINGS CORPORATION is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canadian Organic Sprout Company

Canadian Organic Sprout Company is a Belleville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Invicro

Invicro, A Konica Minolta Company, was founded with a mission of improving the role and function of imaging in translational drug discovery and development. To this effort we offer a suite of services and software with applications ranging from tissue to human, from target identification to Phase IV trials across the entire electromagnetic spectrum of imaging techniques. We start all projects with a data-driven mentality and the knowledge that quality data are the key to solving scientific challenges. Our analytics team is constantly innovating to develop the processes by which true and valuable quantitative information is extracted. Our approach has always been one of a scientific partner and collaborator, offering the service of our 200+ researchers on our team from a broad array of disciplines.

Cellartis AB

Cellartis AB is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boundless Bio

Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.